A-01 Registration at the conference venue Tuesday 18:30-20:00 |
A-02 Opening ceremony and welcome reception Tuesday 20:30-22:30 |
B-01 Registration at the conference venue Wednesday 08:00-08:45 |
B-02 Welcome and Introduction Wednesday 08:45-09:00 |
B-03 Amin Rostami OrBiTo - translating mechanistic knowledge on absorption into predictive models Wednesday 09:00-09:40 |
B-04 Benjamin Guiastrennec Mechanism-based modelling of gastric emptying and bile release in response to caloric intake Wednesday 09:40-10:00 |
B-05 Andrés Olivares-Morales An in silico physiologically-based pharmacokinetic (PBPK) study of the impact of the drug release rate on oral absorption, gut wall metabolism and relative bioavailability Wednesday 10:00-10:20 |
B-06 Coffee break, poster and software session I: posters in Group I (with poster numbers starting with I-) are accompanied by their presenter Wednesday 10:20-11:50 |
B-07 Kapil Gadkar Development of Virtual Population for a Quantitative Systems Pharmacology model Wednesday 11:50-12:10 |
B-08 Maciej Swat PharmML 1.0 - An Exchange Standard for Models in Pharmacometrics Wednesday 12:10-12:30 |
B-09 Marc Gastonguay Proposal for a Web-Based Open Pharmacometrics Curriculum Wednesday 12:30-12:40 |
B-10 Lunch Wednesday 12:40-14:10 |
B-11 Pierre Marquet Model-based personalized medicine in transplantation Wednesday 14:10-14:50 |
B-12 Núria Buil Bruna A step forward toward personalised medicine in oncology: Population modelling for the early prediction of disease progression using biomarkers Wednesday 14:50-15:10 |
B-13 Tea break, poster and software session II: posters in Group II (with poster numbers starting with II-) are accompanied by their presenter Wednesday 15:10-16:30 |
B-14 Julia Korell Application of a model based longitudinal network meta-analysis of FEV1 in COPD trials in clinical drug development Wednesday 16:30-16:50 |
B-15 Sebastian Weber Bayesian Drug Disease Model with Stan - Using published longitudinal data summaries in population models Wednesday 16:50-17:10 |
B-16 Angelica Quartino An integrated natural disease progression model of nine cognitive and biomarker endpoints in patients with Alzheimer's Disease Wednesday 17:10-17:30 |
B-17 Yaming Hang Pharmacokinetic and Pharmacodynamic Analysis of Longitudinal Gd-Enhanced Lesion Count in Subjects with Relapsing Remitting Multiple Sclerosis Treated with Peginterferon beta-1a Wednesday 17:30-17:50 |
C-01 Tram Nguyen Handling data below the quantification limit in viral kinetic modeling for model evaluation and prediction of treatment outcome Thursday 08:45-09:10 |
C-02 Nikolaos Tsamandouras Development of population based approaches to describe the complex pharmacokinetics of simvastatin in different individuals. Bridging the gap between population and physiologically based pharmacokinetic modelling. Thursday 09:10-09:35 |
C-03 Mélanie Wilbaux A dynamic K-PD joint model for the kinetics of CTC (Circulating Tumor Cell) count and PSA concentration during treatment in metastatic castration-resistant prostate cancer Thursday 09:35-10:00 |
C-04 Presentation of Lewis Sheiner student session awards Thursday 10:00-10:05 |
C-05 Coffee break, poster and software session III: posters in Group III (with poster numbers starting with III-) are accompanied by their presenter Thursday 10:05-11:30 |
C-06 Scott Marshall Good Practices in Model Informed Drug Discovery and Development (MID3): Practice, Application, Documentation and Reporting Thursday 11:30-11:50 |
C-07 Terry Shepard How European Regulators are Facilitating the Use of Modelling and Simulation: MSWG History, Activity and Future Thursday 11:50-12:15 |
C-08 Efthymios Manolis EMA qualification of novel methodologies: are we ready for M&S ? Thursday 12:15-12:35 |
C-09 Panel discussion Thursday 12:35-12:50 |
C-10 Lunch Thursday 12:50-14:15 |
C-11 Björn Bornkamp The MCP-Mod methodology - A statistical methodology for dose-response Thursday 14:15-14:40 |
C-12 Vikram Sinha The Role of Model Based Drug Development – Is it time to repaint the canvas? Thursday 14:40-15:15 |
C-13 Tea break, poster and software session IV: posters in Group IV (with poster numbers starting with IV-) are accompanied by their presenter Thursday 15:15-16:40 |
C-14 Camille Vong In silico comparison of MTD determination in a phase I dose-finding framework Thursday 16:40-17:00 |
C-15 Coen van Hasselt Towards early integrated mechanism-based prediction of clinical outcome and cost-effectiveness in castration-resistant prostate cancer Thursday 17:00-17:20 |
D-01 Edouard Ollier Group comparison with fused lasso penalized likelihood: an alternative to test based methods Friday 09:00-09:20 |
D-02 Elin Svensson Prediction of pharmacokinetic interactions for drugs with a long half-life - evidence for the need of model-based analysis Friday 09:40-09:40 |
D-03 Yasunori Aoki Averaged Model Based Decision Making for Dose Selection Studies Friday 09:40-10:00 |
D-04 Preview of PAGE2015 Friday 10:00-10:10 |
D-05 Coffee break Friday 10:10-10:50 |
D-06 Sharon Hori Modeling cancer blood biomarker dynamics in relation to tumor growth Friday 10:50-11:10 |
D-07 Rik de Greef Modeling of tumor size reduction patterns in advanced melanoma under treatment with MK-3475, a potent antibody against PD-1 Friday 11:10-11:30 |
D-08 Pauline Mazzocco A mixed-effect modeling framework to personalize treatment of low-grade glioma patients Friday 11:30-11:50 |
D-09 Nick Holford Power and Type 1 Error of Tumour Size Metrics Used to Predict Survival Friday 11:50-12:10 |
D-10 Closing remarks Friday 12:10-12:20 |
D-11 Audience input for potential PAGE2015 topics Friday 12:20-12:40 |
I-01 Jeroen Elassaiss-Schaap Translational Pharmacokinetic/Pharmacodynamic Model of Tumor Growth Inhibition by the New Anti-PD1 Monoclonal Antibody MK-3475 Wednesday 10:20-11:50 |
I-02 Moran Elishmereni Improved sunitinib therapy in non-small cell lung cancer as predicted by a new mixed-effects model Wednesday 10:20-11:50 |
I-03 Yumi Yamamoto Toward a generic PBPK model to predict drug distribution in human brain Wednesday 10:20-11:50 |
I-04 Farkad Ezzet Dose Response Models for Multiple Endpoints: A Simulation Study Wednesday 10:20-11:50 |
I-05 Floris Fauchet Impact of maternal zidovudine infusions at labor on fetus: a population pharmacokinetic study Wednesday 10:20-11:50 |
I-06 Sylvain Fouliard Cardiac safety monitoring in early oncology trials using optimal design and M&S approach Wednesday 10:20-11:50 |
I-07 Tomoko Freshwater Competitive landscape model using meta-analysis and simulation-based evaluation for Phase IIb study design of MRL-1 being developed for the treatment of rheumatoid arthritis Wednesday 10:20-11:50 |
I-08 Aline Fuchs Impact of medication adherence measurement on antiretroviral drug pharmacokinetics: A retrospective cohort study in HIV patients followed by therapeutic drug monitoring and taking part in a medication-adherence enhancing program Wednesday 10:20-11:50 |
I-09 María José García Sánchez PBPK analysis of doxorrubicin tissue uptake by Simcyp® simulator: influence of gender related variables Wednesday 10:20-11:50 |
I-10 María García-Cremades Pharmacokinetic and Pharmacodynamic analysis of Gemcitabine in pancreatic cancer in mice. Wednesday 10:20-11:50 |
I-11 Marc Gastonguay Proposal for a Web-Based Open Pharmacometrics Curriculum: Results of a Four-Month Pilot Evaluation Wednesday 10:20-11:50 |
I-13 Eva Germovsek Mechanistic Modelling of Total Body CD4 T-cell Counts from Paediatric HIV Patients Undergoing Planned Treatment Interruption Wednesday 10:20-11:50 |
I-14 Ekaterina Gibiansky Population Pharmacokinetics of Obinutuzumab (GA101) in Patients with Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin’s Lymphoma (NHL) Wednesday 10:20-11:50 |
I-15 Leonid Gibiansky Numerical Testing of Assumptions for Target-Mediated Drug Disposition (TMDD) Equations: Why Inexact Model Provides Satisfactory Description? Wednesday 10:20-11:50 |
I-16 Sandra Gil Modeling the Postantifungal Effect of Anidulafungin Against Candida Wednesday 10:20-11:50 |
I-17 Anais Glatard A model-based approach to support NOAEL determination: a simulation case illustrated by a real dataset Wednesday 10:20-11:50 |
I-18 Bojana Golubovic Population pharmacokinetics of sirolimus in adult kidney transplant patients Wednesday 10:20-11:50 |
I-19 Marta Gonzalez In-silico Biopharmaceutical Systems for Provisional Classification of Oral Drugs Wednesday 10:20-11:50 |
I-20 Ignacio Gonzalez-Garcia Simulations of populations with different creatinine clearance range and weight to select the best dose of NV22413 Wednesday 10:20-11:50 |
I-21 Mario Gonzalez Sales Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy volunteers. Wednesday 10:20-11:50 |
I-22 Isabel Gonzalez-Alvarez Semi-physiologic model validation and bioequivalence trials simulation to select the best analyte for acetylsalicylic acid Wednesday 10:20-11:50 |
I-23 Sathej Gopalakrishnan Assessing treatment failure under combination therapy in HIV disease Wednesday 10:20-11:50 |
I-24 Verena Gotta Power of PKPD analysis to detect QTc effect in preclinical setting Wednesday 10:20-11:50 |
I-25 Abhishek Gulati Modeling the effect of interferon beta-1b on contrast enhancing lesions in relapsing-remitting multiple sclerosis Wednesday 10:20-11:50 |
I-26 Serge Guzy Evaluation of Bias and Precision using QRPEM algorithm in Phoenix NLME for discrete data models Wednesday 10:20-11:50 |
I-27 Chihiro Hasegawa Modeling & simulation of ONO-5334, a cathepsin K inhibitor, to support dose selection in osteoporosis Wednesday 10:20-11:50 |
I-28 Michael Heathman Concentration-Response Modeling of Adverse Event Data using a Markov Chain Approach Wednesday 10:20-11:50 |
I-29 Stefanie Hennig Population pharmacokinetics of high dose methotrexate in non-Hodgkin lymphoma patients Wednesday 10:20-11:50 |
I-30 Christoph Hethey Towards a cell-level model to predict bacterial growth under antimicrobial perturbation Wednesday 10:20-11:50 |
I-31 Jules Heuberger The prior subroutine explored: pharmacokinetic modeling of THC Wednesday 10:20-11:50 |
I-32 Mistry Hitesh Virtual Tumour Clinical: translational modelling of vemurafenib, selumetinib and docetaxel inmetastatic melanoma Wednesday 10:20-11:50 |
I-33 Rollo Hoare Modelling CD4 lymphocyte reconstitution following paediatric haematopoietic stem cell transplantation Wednesday 10:20-11:50 |
I-34 Nick Holford Evaluation of NONMEM and Monolix by Parametric Bootstrap Wednesday 10:20-11:50 |
I-35 Xiao Hu Exposure-Response Analysis of Peginterferon beta-1a in Subjects with Relapsing Remitting Multiple Sclerosis Wednesday 10:20-11:50 |
I-36 Kimberley Jackson Population Pharmacokinetic (PK) Modelling of Ketamine and Norketamine in Plasma, Prefrontal Cortex (PFC) and Cerebrospinal Fluid (CSF) after Subcutaneous (SC) Administration of S(+)-Ketamine in Rats. Wednesday 10:20-11:50 |
I-37 Bart Jacobs Model based optimization of a novel controlled release formulation of capecitabine Wednesday 10:20-11:50 |
I-38 Esther Janssen Simulations of vancomycin exposure throughout childhood upon commonly used dosing guidelines: towards a model-based dosing regimen Wednesday 10:20-11:50 |
I-39 Petra Jauslin Comparison of post-prandial glucose control by two GLP-1 receptor agonists (lixisenatide and liraglutide) in type 2 diabetes Wednesday 10:20-11:50 |
I-40 Garrit Jentsch The BAST Clinical Trial Simulator: A computational framework for quantitative risk assessment. Wednesday 10:20-11:50 |
I-41 Jin Jin Longitudinal Safety Modeling and Simulation for Regimen Optimization of Vismodegib in Operable Basal Cell Carcinoma Wednesday 10:20-11:50 |
I-42 Niclas Jonsson A Population PK Analysis of Nebivolol and Valsartan in Combination Therapy Wednesday 10:20-11:50 |
I-43 Marija Jovanovic Effect of Valproic Acid Daily Dose on Phenobarbital Clearance - Nonlinear Mixed Effects Modelling Approach Wednesday 10:20-11:50 |
I-44 Rasmus Juul Kildemoes How Repeated Time To Event (RTTE) modelling of opioid requests after surgery may improve future post-operative pain management Wednesday 10:20-11:50 |
I-45 Ana Novakovic Sample size calculations in multiple sclerosis using pharmacometrics methodology: comparison of a composite score continuous modeling and Item Response Theory approach Wednesday 10:20-11:50 |
I-46 Kristin Karlsson Estimating a Cox proportional hazard model in NONMEM Wednesday 10:20-11:50 |
I-47 Mats Karlsson Item response theory for analyzing placebo and drug treatment in Phase 3 studies of schizophrenia Wednesday 10:20-11:50 |
I-48 Takayuki Katsube Population PK/PD Modeling of Lusutrombopag, Thrombopoietin Receptor Agonist, in Healthy Volunteers for Exploring PK/PD Covariates Wednesday 10:20-11:50 |
I-49 Irene-Ariadne Kechagia A meta-analysis methodology to estimate population pharmacokinetic parameters from reported non-compartmental values with sparse sampling Wednesday 10:20-11:50 |
I-50 Ron Keizer Expected effectiveness of reduced-dose efavirenz Wednesday 10:20-11:50 |
I-51 David Khan Evaluation of Mechanism Based PKPD Model for Antibiotics Wednesday 10:20-11:50 |
I-52 Yukyung Kim Metformin's glucose lowering effect in healthy volunteers receiving an oral glucose tolerance test Wednesday 10:20-11:50 |
I-53 Yo Han Kim Early characterization of ticagrelor using modeling and simulation analysis of the in vitro platelet aggregation test and human pharmacokinetic data Wednesday 10:20-11:50 |
I-55 William Knebel Elastic Cloud Computing in Pharmacometrics: Usage Data and Strategies for Efficient Workflows Wednesday 10:20-11:50 |
I-56 Gilbert Koch Solving Semi-Delay Differential Equations in NONMEM Wednesday 10:20-11:50 |
I-57 Markus Krauß Hierarchical Bayesian-PBPK modeling for physiological characterization and extrapolation of patient populations from clinical data Wednesday 10:20-11:50 |
I-58 Mads Kreilgaard Study design optimization of a morphine analgesia trial using PKPD modelling and simulation Wednesday 10:20-11:50 |
I-59 Ryuji Kubota Population Pharmacokinetics of Ospemifene and Evaluation for Exposure Increase Wednesday 10:20-11:50 |
II-01 Brigitte Lacroix Modeling the anti-drug antibody response in rheumatoid arthritis patients treated with certolizumab pegol Wednesday 15:10-16:30 |
II-02 Celine M. Laffont Population PK modeling and simulation to support dose selection of RBP-7000, a new sustained-release formulation of risperidone, in schizophrenic patients. Wednesday 15:10-16:30 |
II-03 Laure Lalande Population modelling and simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of isoniazid in lungs Wednesday 15:10-16:30 |
II-04 Cédric Laouenan Using pharmacokinetic and viral kinetic modeling to estimate the antiviral effectiveness of telaprevir, boceprevir and Peg-IFN during triple therapy in treatment-experienced HCV infected cirrhotic patients Wednesday 15:10-16:30 |
II-05 Anna Largajolli The OFVPPC: A simulation objective function based diagnostic Wednesday 15:10-16:30 |
II-06 Jean Lavigne Modeling and simulation of dihydroartemisinin (DHA) after administration of Eurartesim® (piperaquine tetraphosphate/DHA) Wednesday 15:10-16:30 |
II-07 Kha Le Population PKPD Modeling of Geographic Atrophy Disease Progression, Target Mediated Disposition and Treatment Effect of Lampalizumab Wednesday 15:10-16:30 |
II-08 Jacob Leander Estimation in stochastic differential mixed-effects models Wednesday 15:10-16:30 |
II-09 Robert Leary Robust Importance Sampling for EM-based NLME Algorithms Wednesday 15:10-16:30 |
II-10 Joomi Lee Population pharmacokinetic analysis of sumatriptan in healthy Korean male subjects Wednesday 15:10-16:30 |
II-11 Giulia Lestini Two-stage adaptive designs in nonlinear mixed-effects models: an evaluation by simulation for a pharmacokinetic (PK) and pharmacodynamic (PD) model in oncology Wednesday 15:10-16:30 |
II-12 Yan Li PK/PD Modeling of Tumor Growth Inhibition in Xenograft Mice to Optimize Experimental Design and Improve Study Efficiency Wednesday 15:10-16:30 |
II-13 Olaf Lichtenberger Evaluation of tetrahydrobiopterin responsiveness in neonates with hyperphenylalaninemia Wednesday 15:10-16:30 |
II-14 Andreas Lindauer A tool for First-in-human PK Prediction Incorporating Experimental Uncertainty Wednesday 15:10-16:30 |
II-15 Jos Lommerse PKPD model of erythropoietin and hemoglobin response in rats following administration of prolyl hydroxylase inhibitors Wednesday 15:10-16:30 |
II-16 Gaohua Lu Developing a mechanistic physiologically based lung model and its application in modelling rifampicin pharmacokinetics in the lung Wednesday 15:10-16:30 |
II-17 Merran Macpherson PPK analysis of Rouvastatin in Children and Adolescents (ages 6 to <18 years of age) with Familial Hypercholesterolemia to Support Regulatory Approval Wednesday 15:10-16:30 |
II-18 Mats Magnusson A Population PK/PD Analysis of Nebivolol and Valsartan Combination Therapy Wednesday 15:10-16:30 |
II-19 Victor Mangas-Sanjuan Semi-mechanistic cell cycle PKPD model of chemotherapy-induced neutropenia Wednesday 15:10-16:30 |
II-20 Andreas Matthios Dosing recommendation for gabapentin in chronic paediatric pain Wednesday 15:10-16:30 |
II-21 Johanna Melin Population pharmacokinetic analysis of hydrocortisone in paediatric patients with adrenal insufficiency Wednesday 15:10-16:30 |
II-22 France Mentré PFIM 4.0: new features for optimal design in nonlinear mixed effects models using R Wednesday 15:10-16:30 |
II-23 Matilde Merino-Sanjuán Simulation of Plasmatic Taurine Levels In Well And Undernourished Rats After Enteral Diet Administration. Wednesday 15:10-16:30 |
II-24 Jay Mettetal Preclinical cardiovascular risk assessment of PPAR-gamma agonist effects based on translational PK/PD modelling Wednesday 15:10-16:30 |
II-25 Enrica Mezzalana A Target-Mediated Drug Disposition model to quantify the relationship between Otelixizumab in vitro concentration and TCR/CD3 engagement Wednesday 15:10-16:30 |
II-26 Raymond Miller Modelling and simulation of the activity of intrinsic Factor Xa following edoxaban treatment Wednesday 15:10-16:30 |
II-27 Iris Minichmayr Target site pharmacokinetics of doripenem in plasma and interstitial space fluid of peripheral tissues Wednesday 15:10-16:30 |
II-28 Dirk Jan Moes Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in liver transplant patients Wednesday 15:10-16:30 |
II-29 Daniel Moj Physiologically-based Pharmacokinetic (PBPK) modeling of the time-dependent drug-drug interaction (DDI) of clarithromycin and midazolam Wednesday 15:10-16:30 |
II-30 Hussain Mulla Simultaneous pharmacokinetic modeling of gentamicin, tobramycin and vancomycin clearance from neonates to adults: towards a semi-physiological function for maturation in glomerular filtration. Wednesday 15:10-16:30 |
II-31 Helen Musther Are PBPK models reporting the right Cmax? Central venous versus peripheral site Wednesday 15:10-16:30 |
II-32 Flora Musuamba-Tshinanu Optimisation of tacrolimus-based immunosuppressive treatment in pediatric solid organ transplantation: A model-based approach. Wednesday 15:10-16:30 |
II-33 Tafireyi Nemaura In silico estimation of oral bioavailability: Implications to estimation of efavirenz PK parameters. Wednesday 15:10-16:30 |
II-34 Ida Neldemo Predicting the absolute neutrophil count with frequent measurements during docetaxel-induced myelosuppression Wednesday 15:10-16:30 |
II-35 Yookhwan Noh Population pharmacokinetics of HM781-36 and its metabolites in patients with advanced solid tumors Wednesday 15:10-16:30 |
II-36 Rikard Nordgren Automatic binning for visual predictive checks Wednesday 15:10-16:30 |
II-37 Joakim Nyberg Simulating large time-to-event trials in NONMEM Wednesday 15:10-16:30 |
II-38 Kayode Ogungbenro A physiologically based pharmacokinetic model for 6-mercaptopurine in adults and children Wednesday 15:10-16:30 |
II-39 Sean Oosterholt Covariate model selection in an Alzheimer disease progression model Wednesday 15:10-16:30 |
II-40 Ingrid Ottevaere Population pharmacokinetics of ALX-0171, an inhaled Respiratory Syncytial Virus (RSV) neutralizing Nanobody. Wednesday 15:10-16:30 |
II-41 Aziz Ouerdani Tumor growth and angiogenesis inhibition modeling: Effects of pazopanib on preclinical and clinical tumor size data Wednesday 15:10-16:30 |
II-42 Katie Owens Population K-PD modelling of lymph node size in lymphoma patients treated with abexinostat, a histone deacetylase inhibitor (HDACi). Wednesday 15:10-16:30 |
II-43 Eirini Panoilia A population PK model for bevacizumab when combined with chemotherapy in patients with metastatic colorectal cancer stage IV Wednesday 15:10-16:30 |
II-44 Sung Min Park Population pharmacokinetics and CYP3A5 genotype effect of S-amlodipine in healthy Korean male subjects Wednesday 15:10-16:30 |
II-45 Zinnia Parra-Guillen Population pharmacokinetic modelling of irosustat in postmenopausal women with oestrogen-receptor positive breast cancer Wednesday 15:10-16:30 |
II-46 Sophie Peigné Paediatric PK predictions and population analysis Wednesday 15:10-16:30 |
II-47 Nathalie Perdaems Translational PKPD modeling of a cardiovascular drug and the interrelationship between blood pressure and heart rate in animals and human Wednesday 15:10-16:30 |
II-48 Jonás Samuel Pérez-Blanco Population pharmacokinetic of doxorubicin and doxorubicinol in hematological patients Wednesday 15:10-16:30 |
II-49 Philippe Pierrillas Preclinical evaluation of the dose-concentration-marker-tumor growth relationship of a new pro-apoptotic compound using population PK-PD modeling Wednesday 15:10-16:30 |
II-50 Elodie Plan Item Response Theory Model as Support for Decision-Making: Simulation Example for Inclusion Criteria in Alzheimer's Trial Wednesday 15:10-16:30 |
II-51 Yulan Qi A Prospective Population Pharmacokinetic (PK) Analysis of Sapropterin Dihydrochloride in Infants and Young Children with Phenylketonuria (PKU) Wednesday 15:10-16:30 |
II-52 Gauri Rao Characterization of Oseltamivir Carboxylate (OC) Disposition using a Reduced Population (POP) Pharmacokinetic (PK) Model Wednesday 15:10-16:30 |
II-53 Yan Ren Effect of Fluticasone Furoate Treatment on Cortisol Circadian Rhythm in Healthy Chinese Subjects Wednesday 15:10-16:30 |
II-54 Renhua Zheng Population Compartmental approaches in bioequivalence studies Wednesday 15:10-16:30 |
II-55 Benjamin Ribba On the use of model-based tumor size metrics to predict survival Wednesday 15:10-16:30 |
II-56 Clémence Rigaux Modeling HbA1c dynamics in type II diabetes mellitus in patients treated with GLP-1 receptor agonist lixisenatide Wednesday 15:10-16:30 |
II-57 Rikke Meldgaard Røge Modelling of Glucose and Insulin profiles in Patients with Type 2 Diabetes Mellitus treated with a GLP-1 analogue Wednesday 15:10-16:30 |
II-58 Hyerang Roh Characterization of Nocturia Patient's Urination Pattern and Assessment of Drug Treatment Using Joint Ordered Categorical Model Wednesday 15:10-16:30 |
II-59 Trine Høyer Rose Dose-concentration-response modelling of inhibin B in controlled ovarian stimulation with FE 999049, a recombinant FSH derived from a human cell-line Wednesday 15:10-16:30 |
II-60 Adedeji Majekodunmi Mixed Effect Modelling in HCV-HIV co-infected Children Wednesday 15:10-16:30 |
III-01 João Abrantes A repeated time-to-event model for epileptic seizures in patients undergoing antiepileptic drug withdrawal during Video-EEG monitoring Thursday 10:05-11:30 |
III-02 Oliver Ackaert Quantification of the effect of AZD5213 on sleep in subjects with Alzheimer’s disease or mild cognitive impairment using a two state Markov model Thursday 10:05-11:30 |
III-03 Rick Admiraal Population pharmacokinetic modeling of Thymoglobulin in children receiving allogeneic-hematopoietic cell transplantation (HCT): towards individualized dosing to improve survival Thursday 10:05-11:30 |
III-04 Ricardo Alvarez Differences in response to scopolamine between young and elderly healthy adults using a modelling approach: reduction in the central cholinergic system in the elderly? Thursday 10:05-11:30 |
III-05 Claire Ambery Bayesian bio-comparability using small sample sizes and quantification of safety risk Thursday 10:05-11:30 |
III-06 Franc Andreu Solduga Pharmacokinetic modeling of enterohepatic circulation of mycophenolic acid in renal transplant patients. Thursday 10:05-11:30 |
III-07 Natalia Aniceto Population Pharmacokinetics-Pharmacogenetics of Efavirenz using Non-Linear Mixed Effects Modeling and Bayesian Estimation Thursday 10:05-11:30 |
III-08 Manel Aouri Population pharmacokinetics and pharmacogenetics analysis of Rilpivirine in HIV-1 infected individuals Thursday 10:05-11:30 |
III-09 Eduardo Asín-Prieto Population Pharmacokinetics of Daptomycin in Critically Ill Patients Thursday 10:05-11:30 |
III-10 Ioanna Athanasiadou Hyperhydration may alter urine pharmacokinetic profile of drugs: A simulation study using budesonide as model drug Thursday 10:05-11:30 |
III-11 Charlotte Barker Synthesising pragmatic and optimal design: NAPPA - a paediatric penicillin population pharmacokinetic study Thursday 10:05-11:30 |
III-12 Ana Bastos Modeling and simulation of temocillin (TMO) in patients with end stage renal disease undergoing haemodialysis Thursday 10:05-11:30 |
III-13 Francesco Bellanti New dosing recommendations in patients receiving deferiprone chelation therapy in the presence of renal complications Thursday 10:05-11:30 |
III-14 Jan Berkhout Mechanism-based approaches to the analysis of comparative effectiveness in osteoporosis Thursday 10:05-11:30 |
III-15 Julie Bertrand Population approach in high-throughput pharmacogenetics: challenging the maximum likelihood approaches and exploration of a Bayesian alternative Thursday 10:05-11:30 |
III-16 Andrzej Bienczak Population Pharmacokinetic Analysis of Efavirenz in African Children using mixture modelling to describe clearance multimodality. Thursday 10:05-11:30 |
III-17 Sebastien Bihorel KIWI: a collaborative platform for modeling and simulation Thursday 10:05-11:30 |
III-18 Roberto Bizzotto Glucose Homeostasis Modeling: Improvement of the Insulin Kinetics Component Thursday 10:05-11:30 |
III-19 Irina Bondareva Population modeling of steady-state pharmacokinetics of carbamazepine (CBZ) and its epoxide metabolite (CBZE) from therapeutic drug monitoring (TDM) data Thursday 10:05-11:30 |
III-20 Jens Markus Borghardt The physiological interpretation of population pharmacokinetic modelling results for inhaled olodaterol Thursday 10:05-11:30 |
III-21 Dean Bottino Operating Characteristics of Tumor Kinetic Response Assessments in Early Phase Oncology Trials Thursday 10:05-11:30 |
III-22 Ari Brekkan Viggosson Optimized Reduced Designs of Pharmacokinetic Clinical Trials Utilizing Target Mediated Drug Disposition Models Thursday 10:05-11:30 |
III-23 Karl Brendel Population Pharmacokinetic modelling for a molecule S and its glucuronide metabolite including enterohepatic recycling Thursday 10:05-11:30 |
III-24 Frances Brightman Predicting clinical response using preclinical data: translational modelling of docetaxel-thalidomide combination treatment in metastatic, castrate-resistant, prostate cancer Thursday 10:05-11:30 |
III-25 Margreke Brill Midazolam pharmacokinetics following semi-simultaneous oral and intravenous administration in morbidly obese patients before and 1 year after bariatric surgery Thursday 10:05-11:30 |
III-26 Claire Brillac Population PK/PD modeling of tumor growth inhibition in tumor bearing mice: a translational strategy to predict clinical efficacy ? Thursday 10:05-11:30 |
III-27 René Bruno Exposure-Response Modeling and Simulation of lucitanib Induced Dose Limiting Toxicities and Response Categories in Patients with Solid Tumors Thursday 10:05-11:30 |
III-28 Jantine Brussee Modelling and simulation of the effect of L-arginine adjunctive therapy on vascular function in patients with moderately severe malaria Thursday 10:05-11:30 |
III-29 Elisa Calvier Use of semi-physiological covariate model for maturation of glucuronidation to scale from adults to children Thursday 10:05-11:30 |
III-30 Ana Catalan-Latorre A Mechanistic Population Pharmacokinetic Model For Taurine In Well And Undernourished Rats Thursday 10:05-11:30 |
III-31 Juan Pablo Cayun Pellizaris Association between genetic, adverse events and pharmacokinetics in testicular cancer patients. Thursday 10:05-11:30 |
III-32 Pascal Chanu Population pharmacokinetic/pharmacodynamic models to support dose selection of daratumumab in multiple myeloma patients Thursday 10:05-11:30 |
III-33 Aziz Chaouch Population pharmacokinetics of oral voriconazole patients undergoing cataract surgery: modelling concentrations in plasma and in the aqueous humour Thursday 10:05-11:30 |
III-34 Chayan Acharya A diagnostic tool for population models using non-compartmental analysis: nca_ppc functionality for R Thursday 10:05-11:30 |
III-35 Chunli Chen Population pharmacokinetic-pharmacodynamic modelling of rifampicin treatment response in a tuberculosis acute mouse model Thursday 10:05-11:30 |
III-36 Manoranjenni Chetty Exploring fixed dose versus body weight based dosing for monoclonal antibodies using physiologically based pharmacokinetic modelling. Thursday 10:05-11:30 |
III-37 Hyangki Choi Population PKPD modeling of moxifloxacin effect on QT interval prolongation from baseline in Korean and Japanese healthy male and female subjects Thursday 10:05-11:30 |
III-39 Eirini Christodoulou Pharmacokinetics of silibinin in mice tissues and serum after peros and intravenous administration as a HP-ß-CD lyophilized product Thursday 10:05-11:30 |
III-40 Jae Yong Chung Ethnic difference of ADAS-Cog Placebo Response in Patients with Alzheimer's Disease Thursday 10:05-11:30 |
III-41 Laurent Claret A simulation study to assess the impact of time to growth estimation shrinkage on overall survival association Thursday 10:05-11:30 |
III-42 Oskar Clewe A bronchoalveolar lavage study design framework for characterization of the rate and extent of pulmonary distribution Thursday 10:05-11:30 |
III-43 Pieter Colin A model-based analysis of IPEC dosing of paclitaxel in rats. Thursday 10:05-11:30 |
III-44 Teresa Collins Performance of composite and serial study designs for estimation of toxicokinetic parameters. Thursday 10:05-11:30 |
III-45 Emmanuelle Comets Population pharmacokinetics of mycophenolate acid and its metabolite in liver transplant patients Thursday 10:05-11:30 |
III-46 Ana Margarita Contreras Sandoval PK/PD modeling of new immunotherapeutic agents in cancer Thursday 10:05-11:30 |
III-47 Paola Coppola Pharmacokinetic assessment of prulifloxacin in patients with renal impairment using population pharmacokinetics modelling and simulations Thursday 10:05-11:30 |
III-48 Damien Cronier A semi-mechanistic PK/PD model of vemurafenib resistance and its rescue by LY2835219, a cyclin-dependent kinase 4/6 inhibitor, in mice bearing human melanoma xenograft tumours Thursday 10:05-11:30 |
III-49 Chantal Csajka Population Pharmacokinetics of Tamoxifen and three of its metabolites in Breast Cancer patients Thursday 10:05-11:30 |
III-50 Chenhui Deng Within subject variability in pharmacometric count data modeling analysis: dynamic inter-occasion variability and stochastic differential equations Thursday 10:05-11:30 |
III-51 William Denney What is Normal? A Meta-Analysis of Phase 1 Placebo Data Thursday 10:05-11:30 |
III-52 Paolo Denti Population pharmacokinetics of cefazolin in children undergoing elective cardiac surgery Thursday 10:05-11:30 |
III-53 Kristin Dickschen Application of Physiologically-Based Pharmacokinetic/Pharmacodynamic Modelling in Oncology Thursday 10:05-11:30 |
III-54 Paul Matthias Diderichsen Dose selection of GLPG0634, a selective JAK1 inhibitor, for rheumatoid arthritis Phase 2B studies: PK/PD modeling of pSTAT1 biomarker and DAS28 clinical response Thursday 10:05-11:30 |
III-55 Thomas Dorlo Sample size estimates for a clinical trial evaluating allometric dosing of miltefosine in children with visceral leishmaniasis in East Africa Thursday 10:05-11:30 |
III-56 Sameer Doshi Assessing the Influence of the Log-Transform Both Sides (LTBS) Approach on the Type 1 and Type 2 Error Rates for Clearance Estimation when using Bayesian Priors Thursday 10:05-11:30 |
III-57 Ignacio Hernández Imaging procedures help compartmental analysis using nonlinear mixed effect models. Application in the field of non-clinical research. Thursday 10:05-11:30 |
III-58 Janna Duong Linking mechanism-based modelling of type 2 diabetes mellitus with cardiovascular endpoints Thursday 10:05-11:30 |
III-59 Thomas Eissing Target validation and lead optimization in drug development for diabetes using a physiologically-based PK/PD model of the glucose-insulin regulatory system Thursday 10:05-11:30 |
IV-01 Stefaan Rossenu Population Pharmacokinetics of MK-3475, a human Anti-PD-1 Monoclonal Antibody in patients with progressive locally advanced or metastatic carcinoma, melanoma, and non-small cell lung carcinoma Thursday 15:15-16:40 |
IV-02 Tarjinder Sahota Interactive population PK/PD model simulations in R Thursday 15:15-16:40 |
IV-03 Maria Luisa Sardu Steady-state equivalence of drug- and biomarker driven models in tumor growth experiments Thursday 15:15-16:40 |
IV-04 Andre Schäftlein Population modeling of the relationship between the pharmacokinetics of the oral thrombin inhibitor dabigatran etexilate and coagulation biomarkers in patients with non-valvular atrial fibrillation from the RE-LY trial Thursday 15:15-16:40 |
IV-05 Emilie Schindler PKPD-Modeling of individual lesion maximal standardized uptake value (SUV) in Gastro-Intestinal Stromal Tumors (GIST) patients treated with sunitinib Thursday 15:15-16:40 |
IV-06 Jan-Frederik Schlender Development of a whole-body PBPK approach to assess the pharmacokinetics of xenobiotics in elderly individuals Thursday 15:15-16:40 |
IV-07 Stephan Schmidt Evaluation of changes in oral drug absorption in preterm neonates for BCS class I and II compounds Thursday 15:15-16:40 |
IV-08 Siti Maisharah Sheikh Ghadzi Are insulin measurements needed in glucose provocation studies? : Comparison of study power using Monte-Carlo Mapped Power (MCMP) method Thursday 15:15-16:40 |
IV-09 Shinji Shimizu PBPK modeling of CNS distribution for risperidone and its active metabolite, paliperidone Thursday 15:15-16:40 |
IV-10 Kwang-Hee Shin A population pharmacokinetic/pharmacodynamic approaches of a peglyated granulocyte-colony stimulating factor (G-CSF) in healthy Korean Thursday 15:15-16:40 |
IV-11 Satoshi Shoji Evaluation of information of prior relative to current data in analysis with prior Thursday 15:15-16:40 |
IV-12 Nelleke Snelder A new model-based approach to compare toxicity of a series of compounds based on their categorical toxicity scores Thursday 15:15-16:40 |
IV-13 Kabir Soeny A Novel Algorithm for Optimizing Dose Regimens and Fixed Dose Combination Ratios Thursday 15:15-16:40 |
IV-14 Mijeong Son Population Pharmacokinetic-Pharmacodynamic modeling of Olemsartan in Healthy Korean Volunteers Thursday 15:15-16:40 |
IV-15 Konstantina Soulele A population pharmacokinetic study of fluticasone/salmeterol in healthy subjects using two different dry powder inhalers Thursday 15:15-16:40 |
IV-16 Christine Staatz A survey of intravenous tobramycin monitoring and dosage adjustment practice in cystic fibrosis patients in Australia and the United Kingdom Thursday 15:15-16:40 |
IV-17 Elisabet Størset Evaluation of dosing strategies to achieve targeted tacrolimus exposure after adult kidney transplantation Thursday 15:15-16:40 |
IV-18 Fran Stringer Evaluating the clinical influence of UGT2B15 genotype on the pharmacodynamic response of the PPAR agonist, sipoglitazar Thursday 15:15-16:40 |
IV-19 Mark Stroh Meta-analysis of Published Efficacy and Safety Data for Docetaxel in Second-Line Treatment of Patients with Advanced Non-Small-Cell Lung Cancer Thursday 15:15-16:40 |
IV-20 Eric Strömberg Design evaluation using a bootstrapped Monte Carlo variance-covariance matrix. Thursday 15:15-16:40 |
IV-21 Kim Stuyckens Modelling and simulation approach to optimize the pharmacological activity during a Phase 1 study of JNJ-42756493, a selective and potent FGFR 1, 2 ,3 and 4 inhibitor. Thursday 15:15-16:40 |
IV-22 Siddharth Sukumaran Development of a Mechanism-based pharmacokinetic model for MMAE conjugated ADCs Thursday 15:15-16:40 |
IV-23 Ahmed Suleiman A survival modeling analysis evaluating the use of positron emission tomography with [(18)F]-fluorodeoxyglucose for predicting the prognosis in advanced non-small cell lung cancer patients first-treated with erlotinib Thursday 15:15-16:40 |
IV-24 Amit Taneja Development of a mechanism-based pharmacokinetic-pharmacodynamic model of prolactin response following administration of D2 antagonists in rats Thursday 15:15-16:40 |
IV-25 Paulo Teixeira Population Pharmacokinetic Model of Valproic Acid in Adult Patients: an Update Thursday 15:15-16:40 |
IV-26 Nadia Terranova An energy based model able to describe the effect of anticancer drugs on tumor growth and host body weight Thursday 15:15-16:40 |
IV-27 Adrien Tessier Contribution of nonlinear mixed effects models and penalised regression approaches in pharmacogenetic population studies Thursday 15:15-16:40 |
IV-29 Melanie Titze A semi-mechanistic model to describe the bidirectional interaction between oncolytic reovirus and in vitro tumor growth of U87-glioblastoma cells Thursday 15:15-16:40 |
IV-30 Iñaki F. Trocóniz Population pharmacokinetic/pharmacodynamic modelling of the analgesic and pupillometry effects of axomadol and its O-demethyl metabolite in healthy subjects Thursday 15:15-16:40 |
IV-31 Sebastian Ueckert Accelerating Monte-Carlo Power Studies through Parametric Power Estimation Thursday 15:15-16:40 |
IV-32 Pavan Vajjah Exposure-response relationship of certolizumab pegol in psoriatic arthritis patients and comparison of ACR 20/50/70 response rates in the two dosage regimens Thursday 15:15-16:40 |
IV-33 Elodie Valade Modified renal function in pregnancy: impact on emtricitabine pharmacokinetics Thursday 15:15-16:40 |
IV-34 Pyry Välitalo Evaluation of gentamicin and tobramycin dosing guidelines for neonates; towards model-based dosing Thursday 15:15-16:40 |
IV-35 Sven van Dijkman A PKPD Hidden Markov Model for Lamotrigine in all age groups Thursday 15:15-16:40 |
IV-36 Coen van Hasselt Development of an integrated model-based framework to support clinical development of antibiotics Thursday 15:15-16:40 |
IV-37 Eline van Maanen Integrating tracer kinetic data with absolute protein concentration measurements in a systems pharmacology model. Application to the APP pathway in CMP rhesus monkeys. Thursday 15:15-16:40 |
IV-38 Anne van Rongen Population pharmacokinetics of a single intravenous dose of midazolam in obese, overweight and non-obese adolescents Thursday 15:15-16:40 |
IV-39 Rob van Wijk Challenges in the evaluation of the preclinical dosing rationale for tuberculosis treatment Thursday 15:15-16:40 |
IV-40 Marc Vandemeulebroecke Identifying neuropsychological domains with high information on early signs of cognitive decline: An application of Item Response Theory in the Basel Study on the Elderly Thursday 15:15-16:40 |
IV-41 Nieves Velez de Mendizabal Analysis of Sleep Changes Induced by Citalopram: A Population Approach Thursday 15:15-16:40 |
IV-42 Swantje Völler Age-Dependent Pharmacokinetics of Doxorubicin in Children with Cancer: Results of the EPOC-MS-001 Study Thursday 15:15-16:40 |
IV-43 Chenguang Wang Population pharmacokinetics of paracetamol across the human age-range from (pre)term neonates, infants, children to adults Thursday 15:15-16:40 |
IV-44 Shaonan Wang Exposure-response analysis of Axomadol in patients suffering from hip and/or knee-joint osteoarthritis pain Thursday 15:15-16:40 |
IV-45 Franziska Weber Evaluation of candidate drugs to induce the redundant gene ABCD2 as an alternative treatment option for X-linked adrenoleukodystrophy Thursday 15:15-16:40 |
IV-46 Thierry Wendling Nonlinear mixed-effects modelling of the oral absorption of mavoglurant following administration of an immediate- and a modified-release formulation in healthy subjects Thursday 15:15-16:40 |
IV-47 Sebastian Wicha Adaptive optimal design for the concentration tiers in time-kill curve experiments. Thursday 15:15-16:40 |
IV-48 Pawel Wiczling PK/PD of propofol and fentanyl in patients undergoing abdominal aortic surgery - the influence of cardiac output and drug interactions Thursday 15:15-16:40 |
IV-49 Wenyuan Xiong PK/PD modeling of the c-Met inhibitor MSC2156119J to establish the recommended Phase II dose Thursday 15:15-16:40 |
IV-50 Shuying Yang Probability of Success with Exposure Response Modelling and Clinical Trial Simulation as a Tool to Support Decision Making Thursday 15:15-16:40 |
IV-51 Huixin Yu Integrated mechanism-based pharmacokinetic model for sunitinib and its active metabolite Thursday 15:15-16:40 |
IV-52 Hinojal Zazo Gómez PK/PD modelling and simulation of stavudine nanoparticles in HIV patients Thursday 15:15-16:40 |
IV-53 Stefan Zeiser Whole-Body PBPK Modeling of Tacrolimus in Healthy Volunteers Thursday 15:15-16:40 |
IV-54 Jianping Zhang Pharmacokinetics of eltrombopag in patients with hepatic impairment Thursday 15:15-16:40 |
IV-55 Liping Zhang A Mechanistic Modeling Approach Characterizing the Interaction of Pharmacokinetics and Pharmacodynamics of a Monoclonal Antibody and the Supply/Synthesis of its target in Cynomolgus Monkey Thursday 15:15-16:40 |
IV-56 Simon Zhou Uncertainty and key factors in assessing drug effect in cell-based and xenograft tumor models in rodents Thursday 15:15-16:40 |
IV-57 Li Zhu Population Pharmacokinetic/Pharmacodynamic Models for the Heart Rate Effects of BMS-820836, a Triple Monoamine Reuptake Inhibitor, in a Thorough QT Study Thursday 15:15-16:40 |
IV-58 Morris Muliaditan Population Pharmacokinetic Meta-Analysis of the Antiretroviral Agent Lamivudine in HIV-Infected Children Thursday 15:15-16:40 |
IV-59 Oscar Della Pasqua Population Pharmacokinetic Meta-Analysis of the Antiretroviral Agent Abacavir in HIV-Infected Children Thursday 15:15-16:40 |